Annual Revenue Growth (Last Twelve Months): BiondVax Pharmaceuticals (SCNI)

The year-over-year sales trajectory for the trailing four quarters demonstrates that the metric has reached the level of 142.50. This trend captures pressure from vaccine industry behemoths, which complicates the competition for government grants. Partnerships with scientific centers for nanobody development provide stability, while a global network of contacts offsets Israeli geopolitical risks, supporting the operational activities of Scinai Immunotherapeutics (SCNI).
scinai.com (SCNI) - metric breakdowns and financial figures

Scinai Immunotherapeutics' operational successes in the CDMO sector and immunotherapy development are reflected in this chart of rolling 12-month year-over-year revenue growth. This indicator measures sales dynamics over a one-year period with daily updates, allowing investors to assess the long-term vector of business expansion, while a stable upward trend may signal impending intensified competition and the risk of declining future margins.